Comparative Pharmacology
Head-to-head clinical analysis: TRAVOPROST versus YUVEZZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVOPROST versus YUVEZZI.
TRAVOPROST vs YUVEZZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Travoprost is a synthetic prostaglandin F2α analog that acts as a selective FP receptor agonist. By binding to FP prostanoid receptors, it increases uveoscleral outflow of aqueous humor, reducing intraocular pressure.
YUVEZZI is not a recognized drug. No mechanism available.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
150 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 45 minutes (range 17–86 minutes) for travoprost free acid in plasma; clinical effect (IOP reduction) persists longer due to prolonged receptor binding.
Clinical Note
moderatePirlindole + Travoprost
"Pirlindole may increase the hypotensive activities of Travoprost."
Clinical Note
moderateTiaprofenic acid + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Carprofen."
Clinical Note
moderateBosentan + Travoprost
Terminal elimination half-life of 8–12 hours; permits twice-daily dosing in most indications
Renal (approximately 20% as unchanged drug and free acid metabolites); biliary/fecal (about 60% as metabolites)
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog
"Bosentan may increase the hypotensive activities of Travoprost."